156 related articles for article (PubMed ID: 25485173)
1. Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.
Hendrick F; Davidoff AJ; Zeidan AM; Gore SD; Baer MR
Medicare Medicaid Res Rev; 2014; 4(4):. PubMed ID: 25485173
[TBL] [Abstract][Full Text] [Related]
2. Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.
Davidoff AJ; Weiss SR; Baer MR; Ke X; Hendrick F; Zeidan A; Gore SD
Leuk Res; 2013 Jun; 37(6):675-80. PubMed ID: 23523473
[TBL] [Abstract][Full Text] [Related]
3. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
Seetasith A; Holdford D; Shah A; Patterson J
Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
[TBL] [Abstract][Full Text] [Related]
4. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
[TBL] [Abstract][Full Text] [Related]
5. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
[TBL] [Abstract][Full Text] [Related]
6. Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece.
Papachristos A; Kani C; Litsa P; Valsami G; Souliotis K; Saridi M; Markantonis S
Consult Pharm; 2016 May; 31(5):271-81. PubMed ID: 27178657
[TBL] [Abstract][Full Text] [Related]
7. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
8. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.
Duong VH; Baer MR; Hendrick F; Weiss SR; Sato M; Zeidan AM; Gore SD; Davidoff AJ
Leuk Res; 2015 Jun; 39(6):586-91. PubMed ID: 25869077
[TBL] [Abstract][Full Text] [Related]
9. Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.
Davidoff AJ; Hendrick FB; Zeidan AM; Baer MR; Stuart BC; Shenolikar RA; Gore SD
J Oncol Pract; 2015 Mar; 11(2):e190-8. PubMed ID: 25563701
[TBL] [Abstract][Full Text] [Related]
10. Trends in Erythropoiesis-stimulating agent use and blood transfusions for chemotherapy-induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
Vega A; Zhang R; Wong HL; Wernecke M; Alexander M; Feng Y; Lo AC; Lufkin B; Ryan Q; Izem R; MaCurdy TE; Kelman JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2021 May; 30(5):626-635. PubMed ID: 33534188
[TBL] [Abstract][Full Text] [Related]
11. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
Yu JM; Shord SS; Cuellar S
J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
[TBL] [Abstract][Full Text] [Related]
12. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.
Wright JD; Neugut AI; Wilde ET; Buono DL; Malin J; Tsai WY; Hershman DL
J Clin Oncol; 2011 Sep; 29(25):3408-18. PubMed ID: 21810679
[TBL] [Abstract][Full Text] [Related]
13. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.
Gabrilove J; Paquette R; Lyons RM; Mushtaq C; Sekeres MA; Tomita D; Dreiling L
Br J Haematol; 2008 Jul; 142(3):379-93. PubMed ID: 18540943
[TBL] [Abstract][Full Text] [Related]
14. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea.
Kang RY; Lee J; Lee YH; Lee HS; Jeong JH; Lee YJ
Int J Clin Pharm; 2012 Aug; 34(4):651-7. PubMed ID: 22729393
[TBL] [Abstract][Full Text] [Related]
15. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
Tsang E; Leitch HA
Ann Hematol; 2016 Jan; 95(1):73-78. PubMed ID: 26453076
[TBL] [Abstract][Full Text] [Related]
16. Pharmacist collaborative practice agreement for the management of anemia in malignant disease with erythropoiesis-stimulating agents.
Weil E; Oxencis C
Support Care Cancer; 2015 Aug; 23(8):2507-13. PubMed ID: 25971214
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
[TBL] [Abstract][Full Text] [Related]
18. Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review.
Henry DH; Langer CJ; McKenzie RS; Piech CT; Senbetta M; Schulman KL; Stepanski EJ
Support Care Cancer; 2012 Sep; 20(9):2089-96. PubMed ID: 22160485
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]